Submit Manuscript  

Article Details


miR-4319 Suppresses the Growth of Esophageal Squamous Cell Carcinoma Via Targeting NLRC5

[ Vol. 13 , Issue. 2 ]

Author(s):

Xiao Hu, Min Wang, Lei Cao, Li Cong, Yujie Gao, Jianwei Lu, Jifeng Feng, Bo Shen and Delin Liu*   Pages 144 - 149 ( 6 )

Abstract:


Background: The functions of microRNAs (miRNAs) in cancer progression have been recognized in recent years. However, the role of miR-4319 in esophageal squamous cell carcinoma (ESCC) remains unclear.

Objective: We aimed to investigate the biological roles of miR-4319 in ESCC progression and the associated mechanisms.

Methods: Real-time PCR was performed to examine the levels of miR-4319 in ESCC cell lines. The effects of miR-4319 and NOD-like receptor (NLR) family, caspase activation and recruitment domain (CARD) domain containing 5 (NLRC5) on cell proliferation and cell cycle progression were evaluated using MTT assay, colony formation and flow cytometry assays. Bioinformatics techniques and luciferase reporter assay were applied to validate NLRC5 as a miR-4319 target.

Results: The miR-4319 expression was lower in ESCC cells than in the normal cell line. The expression of miR-4319 repressed cell growth and induced cell cycle arrest. NLRC5 was validated as a direct downstream target of miR-4319. Overexpression of NLRC5 potentiated the effects of miR-4319 on cell growth and cell cycle distribution.

Conclusion: Our results demonstrated that miR-4319 might function as a tumor suppressor by targeting NLRC5 in ESCC.

Keywords:

miR-4319, NLRC5, esophageal squamous cell carcinoma, cell growth, cell cycle, cell culture.

Affiliation:

Department of Oncology, Suqian First Hospital, Suqian, 223800, The Pain Clinic, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing 210009, Department of Oncology, Suqian First Hospital, Suqian, 223800, Department of Oncology, Suqian First Hospital, Suqian, 223800, Department of Oncology, Suqian First Hospital, Suqian, 223800, Department of Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing 210009, Department of Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing 210009, Department of Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing 210009, Department of Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing 210009

Graphical Abstract:



Read Full-Text article